Galmed Pharmaceuticals – About the Company

galmed_logo
Galmed Pharmaceuticals (NasdaqCM: GLMD) is a clinical stage biopharmaceutical company developing treatments for diseases of the liver. The Company’s lead product candidate is aramchol, a synthetic fatty acid/bile acid conjugate for the treatment of nonalcoholic steatohepatitis (NASH). Galmed has released positive Phase IIa results for this program and is planning to initiate a 240 patient Phase IIb with aramchol in the second half of 2014.